Navigation Links
Regeneron Announces March 2011 Investor Conference Presentations
Date:2/23/2011

TARRYTOWN, N.Y., Feb. 23, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011

  • RBC Capital Markets' 2011 Healthcare Conference at 10:00 a.m. Eastern Time on Wednesday, March 2, 2011

  • Cowen and Company 31st Annual Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, March 8, 2011

  • Barclays Capital 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Wednesday, March 16, 2011

  • The sessions may be accessed through the Company’s web site, www.regeneron.com, on the Investor Relations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.

    Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.

    Peter DworkinInvestor Relations

    Corporate Communications914.345.7799

    914.345.7800michael.aberman@regeneron.com

    peter.dworkin@regeneron.com
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/28/2017)... DUBLIN , Feb 28, 2017 ... "Digestive Enzyme Supplements Market Forecasts 2014-2025" report to their ... ... reach USD 1.6 billion by 2025. Growing consumer awareness regarding ... good health is expected to stimulate industry growth over the ...
    (Date:2/27/2017)... 27, 2017 Halyard Health, Inc. (NYSE: ... and provided its 2017 outlook and related key planning assumptions. ... $410 million, a 2 percent increase compared to the prior ... 2016 was $10 million compared to net income of $15 ... net income was $24 million compared to adjusted net income ...
    (Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
    Breaking Medicine Technology:
    (Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... Coach Institute (HCI) announced a new partnership through which HCI students, faculty, ... coaching curriculum and practices. The partnership also enables the HCI community to receive ...
    (Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... Overl.ai Inc., a healthcare automation intelligence company based in New York. , “Ensuring ... ensuring the provider’s workflow remains unaltered. Those two fundamental reasons are the reasons ...
    (Date:2/27/2017)... ... ... Bo Chen, PhD is the recipient of the 2017 ASLMS Dr. Horace ... Session at ASLMS 2017, the Annual Conference of the American Society for Laser Medicine ... , During the Plenary Session on April 7, Dr. Chen will give his ...
    (Date:2/27/2017)... ... February 27, 2017 , ... ... Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation in ... body, these individual customized retreats offer the winter-weary soul an excellent opportunity to ...
    (Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, ... that occurs when the bacteria in plaque infect the gums and other tissues supporting ... and root planing or SRP, and can include surgical therapies if the condition has ...
    Breaking Medicine News(10 mins):